Historical shareholding details of
Calamos Advisors LLC
holdings in Bristol-Myers Squibb Co. (BMY)
Monthly changes of
Calamos Advisors LLC
shareholding in Bristol-Myers Squibb Co.
over the previous
months
Month
|
Name |
Total no. shares held |
Percent Holding |
Mar 31, 2025
|
Calamos Advisors Llc
|
665,868
|
0.03%
|
|
Feb 28, 2025
|
Calamos Advisors Llc
|
665,868
|
0.03%
|
|
Jan 31, 2025
|
Calamos Advisors Llc
|
665,868
|
0.03%
|
|
Dec 31, 2024
|
Calamos Advisors Llc
|
623,998
|
0.03%
|
Dec 31, 2024
|
Calamos Advisors Llc
|
665,868
|
0.03%
|
|
Nov 30, 2024
|
Calamos Advisors Llc
|
665,868
|
0.03%
|
|
Oct 31, 2024
|
Calamos Advisors Llc
|
665,868
|
0.03%
|
|
Sep 30, 2024
|
Calamos Advisors Llc
|
623,998
|
0.03%
|
Sep 30, 2024
|
Calamos Advisors Llc
|
679,473
|
0.03%
|
|
Aug 31, 2024
|
Calamos Advisors Llc
|
679,473
|
0.03%
|
|
Jul 31, 2024
|
Calamos Advisors Llc
|
789,555
|
0.04%
|
|
Jun 30, 2024
|
Calamos Advisors Llc
|
642,306
|
0.03%
|
Jun 30, 2024
|
Calamos Advisors Llc
|
808,889
|
0.04%
|
|
May 31, 2024
|
Calamos Advisors Llc
|
808,042
|
0.04%
|
|
Apr 30, 2024
|
Calamos Advisors Llc
|
821,717
|
0.04%
|
|
Mar 31, 2024
|
Calamos Advisors Llc
|
660,662
|
0.03%
|
Mar 31, 2024
|
Calamos Advisors Llc
|
821,603
|
0.04%
|
|
Feb 29, 2024
|
Calamos Advisors Llc
|
821,603
|
0.04%
|
|
Jan 31, 2024
|
Calamos Advisors Llc
|
829,513
|
0.04%
|
|
Dec 31, 2023
|
Calamos Advisors Llc
|
673,769
|
0.03%
|
Dec 31, 2023
|
Calamos Advisors Llc
|
828,967
|
0.04%
|
|
Nov 30, 2023
|
Calamos Advisors Llc
|
828,887
|
0.04%
|
|
Oct 31, 2023
|
Calamos Advisors Llc
|
828,789
|
0.04%
|
|
Sep 30, 2023
|
Calamos Advisors Llc
|
680,102
|
0.03%
|
Sep 30, 2023
|
Calamos Advisors Llc
|
828,386
|
0.04%
|
|
Aug 31, 2023
|
Calamos Advisors Llc
|
835,983
|
0.04%
|
|
Jul 31, 2023
|
Calamos Advisors Llc
|
952,280
|
0.05%
|
|
Jun 30, 2023
|
Calamos Advisors Llc
|
681,613
|
0.03%
|
Jun 30, 2023
|
Calamos Advisors Llc
|
1,125,583
|
0.05%
|
|
May 31, 2023
|
Calamos Advisors Llc
|
1,126,014
|
0.05%
|
|
Mar 31, 2023
|
Calamos Advisors Llc
|
926,139
|
0.04%
|
View all ownership details of Bristol-Myers Squibb Co.